| Program | Indication | Target | Development | ||||
|---|---|---|---|---|---|---|---|
| R&D | Nonclinical | Phase I | Phase II | Phase III | |||
| AB001 1) | CD20-positive B-cell non-Hodgkin lymphoma |
CD20 | |||||
| AB002 (AB001 + ICI) |
CD20-positive B-cell non-Hodgkin lymphoma |
CD20 | |||||
| ABP001 2) | Solid Tumor | TBD | |||||
1)AB001: an autologous CAR-T therapy for non-Hodgkin lymphoma, demonstrating exceptional efficacy
and a robust safety profile, as validated through Investigator-Initiated Trials (IITs).
2)ABP001: AbBio is actively developing advanced sCAR-T therapies designed to address a broad spectrum of solid tumors.
We plan to evaluate their efficacy and safety through upcoming preclinical and clinical studies.
